TWIST1 expression is associated with high-risk neuroblastoma and promotes primary and metastatic tumor growth

M, Sepporta; Praz, Viviane; Bourloud, Katia Balmas; Joseph, Jean-Marc; Jauquier, Nicolas; Riggi, Nicolò; K, Nardou-Auderset; Petit, Arnaud; Scoazec, Jean‐Yves; Sartelet, Hervé; Renella, Raffaele; Mühlethaler-Mottet, Annick

doi:10.1038/s42003-021-02958-6

Cited by 3 publications

(2 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 648 Twist is expressed in mesodermal and ectodermal-derived tissues, and it has been found that Twsit1 and Twsit2 which are structurally homologous are overexpressed in multiple human cancers. 647 , 648 Twsit1 overexpression has been confirmed to be strongly associated with aggressiveness and metastasis in cancer patients, including sarcoma, glioma, melanoma, ESCC, 649 neuroblastoma, 650 cervical cancer, 651 RCC, 652 and hematological malignancies including AML, chronic myeloid leukemia (CML), ALL, CLL, lymphomas. 653 In CML patients, the increased expression of Twist is related to tumor progression, tumor staging, and drug resistance, and Twist can be applied as a biomarker to assess MRD.…”

Section: Classification Of Tumor Biomarkersmentioning

confidence: 99%

Tumor biomarkers for diagnosis, prognosis and targeted therapy

Zhou,

Tao,

Qiu

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

Tumor biomarkers, the substances which are produced by tumors or the body’s responses to tumors during tumorigenesis and progression, have been demonstrated to possess critical and encouraging value in screening and early diagnosis, prognosis prediction, recurrence detection, and therapeutic efficacy monitoring of cancers. Over the past decades, continuous progress has been made in exploring and discovering novel, sensitive, specific, and accurate tumor biomarkers, which has significantly promoted personalized medicine and improved the outcomes of cancer patients, especially advances in molecular biology technologies developed for the detection of tumor biomarkers. Herein, we summarize the discovery and development of tumor biomarkers, including the history of tumor biomarkers, the conventional and innovative technologies used for biomarker discovery and detection, the classification of tumor biomarkers based on tissue origins, and the application of tumor biomarkers in clinical cancer management. In particular, we highlight the recent advancements in biomarker-based anticancer-targeted therapies which are emerging as breakthroughs and promising cancer therapeutic strategies. We also discuss limitations and challenges that need to be addressed and provide insights and perspectives to turn challenges into opportunities in this field. Collectively, the discovery and application of multiple tumor biomarkers emphasized in this review may provide guidance on improved precision medicine, broaden horizons in future research directions, and expedite the clinical classification of cancer patients according to their molecular biomarkers rather than organs of origin.

show abstract

Section: Classification Of Tumor Biomarkersmentioning

confidence: 99%

Tumor biomarkers for diagnosis, prognosis and targeted therapy

Zhou,

Tao,

Qiu

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

show abstract

“…Twist1 is a highly conserved member of the basic helix-loop-helix proteins and is responsible for the transcriptional regulation of mesenchymal cell lineages [ 21 ]. Several studies have demonstrated that the overexpression of Twist1 is upregulated in several cancer types including breast, liver, prostate, melanomas, and endometrial cancer [ 28 – 31 ]. A study by Sun et al has shown that Twist1 expression is correlated with vascular formation in HCC [ 32 ].…”

Section: Introductionmentioning

confidence: 99%

Role of pelitinib in the regulation of migration and invasion of hepatocellular carcinoma cells via inhibition of Twist1

et al. 2023

View full text Add to dashboard Cite

Background Overexpression of Twist1, one of the epithelial-mesenchymal transition-transcription factors (EMT-TFs), is associated with hepatocellular carcinoma (HCC) metastasis. Pelitinib is known to be an irreversible epidermal growth factor receptor tyrosine kinase inhibitor that is used in clinical trials for colorectal and lung cancers, but the role of pelitinib in cancer metastasis has not been studied. This study aimed to investigate the anti-migration and anti-invasion activities of pelitinib in HCC cell lines. Methods Using three HCC cell lines (Huh7, Hep3B, and SNU449 cells), the effects of pelitinib on cell cytotoxicity, invasion, and migration were determined by cell viability, wound healing, transwell invasion, and spheroid invasion assays. The activities of MMP-2 and -9 were examined through gelatin zymography. Through immunoblotting analyses, the expression levels of EMT-TFs (Snail1, Twist1, and ZEB1) and EMT-related signaling pathways such as mitogen-activated protein kinases (MAPKs) and Akt signaling pathways were measured. The activity and expression levels of target genes were analyzed by reporter assay, RT-PCR, quantitative RT-PCR, and immunoblotting analysis. Statistical analysis was performed using one-way ANOVA with Dunnett's Multiple comparison tests in Prism 3.0 to assess differences between experimental conditions. Results In this study, pelitinib treatment significantly inhibited wound closure in various HCC cell lines, including Huh7, Hep3B, and SNU449. Additionally, pelitinib was found to inhibit multicellular cancer spheroid invasion and metalloprotease activities in Huh7 cells. Further investigation revealed that pelitinib treatment inhibited the migration and invasion of Huh7 cells by inducing Twist1 degradation through the inhibition of MAPK and Akt signaling pathways. We also confirmed that the inhibition of cell motility by Twist1 siRNA was similar to that observed in pelitinib-treated group. Furthermore, pelitinib treatment regulated the expression of target genes associated with EMT, as demonstrated by the upregulation of E-cadherin and downregulation of N-cadherin. Conclusion Based on our novel finding of pelitinib from the perspective of EMT, pelitinib has the ability to inhibit EMT activity of HCC cells via inhibition of Twist1, and this may be the potential mechanism of pelitinib on the suppression of migration and invasion of HCC cells. Therefore, pelitinib could be developed as a potential anti-cancer drug for HCC.

show abstract